logo-loader

XPhyto Therapeutics takes a major step forward launching first commercial Biosensor for Oral Inflammation

Published: 19:12 31 Aug 2021 BST

XPhyto Therapeutics CEO Hugh Rogers joined Steve Darling from Proactive to share details the company and their partner 3a-diagnostics have successfully registered their first biosensor test in oral inflammation with the German authorities.

Rogers telling Proactive this will be an at-home self-check that can be performed without the need for specific medical knowledge or training, analytical equipment or even a power supply.

Roger saying, this biosensor,  placed on the tongue, the thin film dissolves and, after 5 minutes, the biosensor releases a bitter taste in case of oral inflammation.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 52 minutes ago